Duchenne Muscular Dystrophy Treatment Market By Therapeutic Approach (Corticosteroids and Conventional Therapies, Exon-Skipping Therapies, Gene Therapy and Gene Replacement, Nonsteroidal Disease-Modifying Therapies); By Route of Administration (Oral Administration, Intravenous Administration, Subcutaneous and Other Routes); By Distribution Channel (Hospital Pharmacies and Specialized Clinics, Retail and Specialty Pharmacies, Online and Specialty Mail-Order Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Duchenne Muscular Dystrophy Treatment Market: Gene-Based Therapies Redefine the Economics of Lifelong Care – (Updated On: 24th-Sep-2026)

The Global Duchenne Muscular Dystrophy Treatment Market was valued at USD 3.80 billion in 2025 and is projected to reach USD 10.65 billion by 2032, expanding at a CAGR of 15.85% during 2026–2032, according to Strategic Market Research.

 

Duchenne muscular dystrophy (DMD), a rare and severe inherited neuromuscular disorder characterized by progressive muscle degeneration caused by mutations in the DMD gene and the absence of functional dystrophin protein.

 

The Duchenne muscular dystrophy (DMD) treatment market is transitioning from long-term corticosteroid management toward disease-modifying therapies, driven by rising adoption of gene-based approaches and expanded treatment access. DMD affects approximately 19.8 per 100,000 live male births globally, creating a defined patient population for emerging therapies. Corticosteroids including prednisone, deflazacort, and vamorolone remain the standard pharmacological foundation, with around 63% of U.S. patients receiving corticosteroid therapy. The commercial landscape is being reshaped by micro-dystrophin gene therapy, with more than 1,200 patients globally treated with Elveys across clinical trials and commercial use

 

Advanced therapeutic platforms, including AAV-based micro-dystrophin gene transfer, RNA-based exon skipping, and next-generation genetic medicines, are increasingly targeting the underlying dystrophin deficiency. Technologies developed by Sarepta Therapeutics and Solid Biosciences use AAV-mediated gene delivery and micro-dystrophin constructs to promote dystrophin expression, potentially improving muscle function and expanding treatment possibilities for patients with Duchenne muscular dystrophy.

 

Overall, the DMD treatment market is moving from long-term symptom control toward increasingly personalized disease modification. A clearly identifiable genetic cause, sustained treatment requirements, high corticosteroid utilization, mutation-specific drug eligibility, and the emergence of gene-based therapies are collectively increasing treatment value per patient and creating a more diversified commercial opportunity across different stages of DMD progression.

 

DMD Revenue Leaders and Growth Frontiers: Genetic Intervention Reshapes Treatment Economics

Therapeutic Approach: Corticosteroids Retain Scale as Gene Replacement Gains Momentum

Corticosteroids Anchor Current DMD Treatment Demand

Corticosteroids & Conventional Therapies represent the leading therapeutic approach segment, accounting for a 39% share valued at USD 1.482 billion in 2025 revenue, and are expected to expand at a CAGR of 8.0% during 2026–2032. Corticosteroids remain the foundation of Duchenne muscular dystrophy (DMD) management, with prednisone and deflazacort helping delay muscle deterioration, extend independent walking ability, and preserve respiratory and cardiac function. Alongside steroid therapy, multidisciplinary care including physical therapy, cardiac monitoring, respiratory support, and emerging options such as vamorolone, exon-skipping therapies, and gene therapy platforms like Elevidys are improving long-term disease management outcomes.

Gene Therapy and Gene Replacement Set the Fastest Growth Pace

Gene Therapy & Gene Replacement account for 21% of the Duchenne Muscular Dystrophy (DMD) treatment market, representing USD 0.798 billion in 2025 revenue, and are expected to witness the fastest growth rate at a CAGR of 25.5% during 2026–2032. This segment is expanding due to the advancement of AAV-based gene delivery platforms that introduce micro-dystrophin genes into muscle cells to restore dystrophin production. Therapies such as Elevidys (delandistrogene moxeparvovec) aim to slow functional decline by enabling cells to produce a shortened dystrophin protein, although these treatments are designed to preserve muscle function rather than reverse existing damage.

 

Administration Pathways: Oral Treatment Leads as Intravenous Genetic Delivery Expands

Oral Therapies Sustain Long-Term At-Home DMD Management

Oral administration remains the leading delivery route in the Duchenne Muscular Dystrophy (DMD) treatment landscape, accounting for a 43% share and generating USD 1.634 billion in 2025 revenue. The segment is projected to grow at a CAGR of 10.0% during 2026–2032, supported by widespread use of oral corticosteroids such as prednisone, deflazacort, and vamorolone, along with newer therapies such as oral givinostat (Duvyzat). These therapies provide convenient at-home management, helping maintain long-term anti-inflammatory and disease-modifying treatment adherence across DMD patients.

Intravenous Delivery Becomes the Gateway to Advanced DMD Therapies

Intravenous (IV) Administration represents a 38% share of the Duchenne muscular dystrophy (DMD) treatment delivery market, valued at USD 1.444 billion in 2025 revenue, and is expected to witness the fastest growth with a CAGR of 21.5% during 2026–2032. IV delivery has become a critical pathway for advanced DMD therapies, enabling systemic circulation of gene therapies such as Elevidys and exon-skipping treatments including casimersen, eteplirsen, and viltolarsen. By distributing therapeutic molecules across skeletal, respiratory, and cardiac muscle tissues, IV administration supports broader disease-targeted treatment coverage compared with localized delivery approaches.

 

Specialized Delivery Networks: Advanced Therapies Concentrate Care in Clinical Treatment Hubs

Hospital Pharmacies and Specialized Clinics Lead Both Scale and Growth

Hospital Pharmacies & Specialized Clinics represent the leading and fastest-expanding distribution channel, accounting for 57% of the Duchenne Muscular Dystrophy (DMD) treatment market with USD 2.166 billion in 2025 revenue and projected to grow at a CAGR of 18.3% during 2026–2032. The increasing adoption of high-cost disease-modifying therapies, including gene therapies and exon-skipping treatments, has strengthened the role of specialty pharmacies and neuromuscular clinics as essential care delivery hubs. These channels manage complex therapy storage, reimbursement coordination, patient monitoring, and long-term treatment continuity, driving their accelerated market expansion.

 

Regional Momentum: North America Leads as Asia-Pacific Accelerates DMD Treatment Access

North America Anchors DMD Revenue Through Early Access and Specialist Infrastructure

North America dominates the global Duchenne Muscular Dystrophy (DMD) treatment landscape, accounting for a 56% share valued at USD 2.128 billion in 2025 revenue. The region’s leadership is supported by early diagnosis initiatives, advanced clinical trial infrastructure, strong adoption of innovative therapies, and well-established healthcare systems. With continued investment in gene therapies and disease-modifying treatments, the North American DMD treatment market is projected to expand at a CAGR of 15.8% during 2026–2032.

Asia-Pacific Sets the Growth Pace Through Expanding Diagnosis and Treatment Capacity

Asia-Pacific (APAC) region is expanding rapidly, positioning it as the fastest-growing regional market globally. APAC accounted for a 14% share of the DMD treatment market, representing USD 0.532 billion in revenue in 2025. The region is projected to achieve a CAGR of 20.0% during 2026–2032, driven by improving access to advanced therapies, increasing diagnosis rates, expanding clinical trial activity, and growing investment in rare disease treatment infrastructure across major Asian healthcare markets.

 

Competitive Landscape: Genetic Medicines and Next-Generation Platforms Redefine DMD Competition

Sarepta Therapeutics: A Multi-Platform Genetic-Medicine Portfolio Anchors DMD Leadership

Sarepta Therapeutics has one of the broadest commercial DMD portfolios, spanning AAV-mediated micro-dystrophin gene therapy and mutation-specific exon-skipping medicines. Its Elevidys uses an AAVrh74 vector to deliver a micro-dystrophin transgene and remains the only FDA-approved gene therapy for DMD; the current U.S. indication covers ambulatory patients aged four years and older with a confirmed DMD mutation. More than 1,200 patients globally have received Elevidys across clinical and real-world settings. Sarepta also commercializes Exondys 51, Vyondys 53, and Amondys 45, extending its presence across multiple genetically defined DMD populations. In three-year EMBARK data, Elevidys-treated patients showed a 73% slower decline in Time to Rise and 70% slower decline in 10-meter walk/run versus an external control group.

Santhera Pharmaceuticals: Agamree Expands the Corticosteroid Treatment Base

Santhera Pharmaceuticals has established a growing commercial position through Agamree (vamorolone), a novel corticosteroid approved in the U.S. for DMD patients aged two years and older. Its pivotal study included 121 boys across 33 sites in 11 countries. Commercial adoption has expanded internationally: Santhera reported that approximately 40% of corticosteroid-using DMD patients in Germany had received Agamree, while Austria exceeded 50% penetration within its steroid-treated DMD population. In the U.S., partner Catalyst reported USD 117 million in 2025 Agamree sales, while approximately 90% of U.S. DMD Centers of Excellence had started using the therapy.

Pipeline and Commercial Competitors: Mutation-Specific and Cell-Based Therapies Broaden DMD Treatment Choice

• Italfarmaco — Developed Duvyzat (givinostat), an oral HDAC inhibitor approved for DMD; the 179-patient Phase 3 EPIDYS trial reported 40% less cumulative decline in NSAA items, supporting its role as a mutation-independent disease-modifying option.

• NS Pharma — Commercializes Viltepso (viltolarsen), an antisense oligonucleotide administered once weekly at 80 mg/kg intravenously for patients with mutations amenable to exon 53 skipping, a genetic group estimated to represent roughly 8–10% of DMD patients.

• Solid Biosciences — Is advancing SGT-003, a next-generation investigational micro-dystrophin gene therapy; 53 participants had been dosed in the Phase 1/2 INSPIRE DUCHENNE program by June 2026, while Phase 3 development has begun.

• Capricor Therapeutics — Is developing deramiocel, an investigational cell therapy targeting functional impairment associated with DMD; its BLA remains under FDA review, with the current PDUFA target date extended to November 22, 2026 following submission of additional Phase 3 HOPE-3 data and analyses.

 

Analyst Perspective: Durable Muscle Preservation Becomes the New Measure of DMD Treatment Value

The Duchenne muscular dystrophy treatment market is entering a period where therapeutic value is increasingly defined by how directly a treatment can alter the underlying disease pathway rather than simply manage progressive symptoms. Genetic confirmation is becoming central to treatment selection, while micro-dystrophin gene transfer, exon-skipping technologies, and mutation-independent disease-modifying therapies are creating distinct commercial pathways across the DMD population. The strongest opportunities are emerging around earlier genetic identification, broader treatment eligibility, durable muscle-function preservation, and next-generation delivery platforms. Companies that can demonstrate sustained functional benefit while improving treatment accessibility and long-term safety are positioned to capture greater value as DMD care moves toward increasingly personalized and disease-modifying intervention.

 

Duchenne Muscular Dystrophy Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.80 Billion
Revenue Forecast in 2032	USD 10.65 Billion
Overall Growth Rate	CAGR of 15.85% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Therapeutic Approach, By Route of Administration, By Distribution Channel, By Geography
By Therapeutic Approach	Corticosteroids & Conventional Therapies, Exon-Skipping Therapies, Gene Therapy & Gene Replacement, Nonsteroidal Disease-Modifying Therapies
By Route of Administration	Oral Administration, Intravenous (IV) Administration, Subcutaneous & Other Routes
By Distribution Channel	Hospital Pharmacies & Specialized Clinics, Retail & Specialty Pharmacies, Online & Specialty Mail-Order Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expanding use of gene-based therapies, high corticosteroid utilization, mutation-specific treatment eligibility, improving genetic diagnosis, development of exon-skipping and mutation-independent therapies, and specialized treatment infrastructure
Customization Option	Available upon request